Histiocytic Disorder Follow-up Study

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jun 13, 2023

Keywords

ClinConnect Summary

The Histiocytic Disorder Follow-up Study is a clinical trial that aims to understand the long-term effects of histiocytic disorders, which are a group of rare diseases affecting the immune system. The study will look at how these conditions impact patients' overall health, including any chronic pain, mental health issues, and how often they need medical care. It will also investigate how these disorders affect the quality of life and overall survival of those diagnosed with them.

Anyone diagnosed with a histiocytic disorder, such as Langerhans cell histiocytosis or Erdheim-Chester disease, can participate, regardless of their age or gender. There are no specific exclusions for this study, meaning almost anyone with a diagnosis can join. Participants can expect to share their health experiences and may be asked about their medical history and how the disorder has affected their daily lives. This research is crucial for better understanding these diseases and improving care for those who live with them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of histiocytic disorder at any age
• • 1. Langerhans cell histiocytosis,
• • 2. Erdheim-Chester disease,
• • 3. Rosai-Dorfman disease,
• • 4. Xanthogranuloma,
• • 5. Mixed histiocytosis
• • 6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)
• • 7. Hemophagocytic lymphohistiocytosis
• Exclusion Criteria:
• • None